Financial Performance - ParagonCare achieved revenue of over $3.6 billion in FY25[31, 51, 53], reflecting an 8.3% increase in underlying revenue compared to the proforma FY24[55] - Underlying EBITDA reached $95.2 million in FY25[31, 52], a 3% increase from the proforma FY24[55] - Underlying Net Profit After Tax (excluding PPA) was $31.2 million in FY25[52, 55], representing a 9.5% increase compared to the proforma FY24[55] - Statutory EBITDA increased significantly by 97.5% to $88.5 million in FY25[53, 55], while Statutory Net Profit After Tax increased by 151.2% to $20.6 million[53, 55] Business Segments - Wholesale sales contributed $3.0 billion to the revenue, showing an 8% increase[56] - Medical Technology sales reached $298 million, a 1% increase[57] - Contract Logistics sales grew by 25% to $336 million[60, 63] - Clinical Manufacturing sales increased by 9% to $25 million[60] - Pharmacy sales grew by 11.6%, with retail pharmacy growth outpacing the market at 23.4%[58] Strategic Initiatives and Integration - The company is executing a "3-2-1" strategic initiative (Three Businesses, Two Years, One Team) to integrate merged businesses[44, 46, 87] - The company achieved $5 million in annual synergies in FY25 and is on track for $12 million in FY26[69, 85] - The company is integrating various entities onto the JDE ERP system, with completion across ANZ expected by the end of FY26[45] Balance Sheet and Cash Flow - Net debt increased to $214.8 million[55], with a Net Debt: EBITDA ratio of 2.26x[55] - Operating cash flows were impacted by a $57 million receivable from a retail pharmacy group[73] - The company secured a revised $400 million debt facility with ScotPac[48, 71] Asia Pacific (APAC) Region - Asia's total revenue from Medical Technology grew by 20% to $101.3 million[81] - The Aesthetics business drove growth in Asia due to new products and increased promotional activity[82]